Application of Xiaojin pills in preparation of medicine for treating and / or preventing abdominal aortic aneurysm

Through research on Xiaojin Pills and animal experiments, it was found that it can inhibit the growth and incidence of abdominal aortic aneurysms, solved the problem of lack of effective drugs for the treatment of abdominal aortic aneurysms in the prior art, provided new prevention and treatment methods, significantly reducing the number of treatments. The diameter and incidence of the abdominal aorta and protect the vascular structure.

CN119074814AActive Publication Date: 2024-12-06PEKING UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411085533.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-12-06
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

Existing drugs have not yet been effectively cured or prevented abdominal aortic aneurysms, and surgical repair is required for patients with aortic diameter greater than 5.5 cm, while patients with a 3.0-5.4 cm can only be closely monitored, and effective drug intervention methods are lacking.

Method used

Xiaojin Pills were used to treat mice at different concentrations of drugs, and the growth inhibitory effect of its abdominal aortic aneurysm was detected. It was found that Xiaojin Pills could inhibit the diameter growth and incidence of abdominal aorta, and had the function of protecting vascular smooth muscle cells and elastic fibers. Inhibit tumor formation.

Benefits of technology

Xiaojin Pills have been verified through animal experiments and have shown their effectiveness in preventing and treating abdominal aortic aneurysms, providing new potential methods for the prevention and treatment of abdominal aortic aneurysms, which can significantly reduce the diameter and incidence of abdominal aortic arteries and protect Vascular structure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074814A_ABST
    Figure CN119074814A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to application of Xiaojin pills in preparation of medicine for treating and / or preventing abdominal aortic aneurysm. The Chinese patent medicine Xiaojin pills are commercially available medicines and are administered in an oral administration manner. Animal experiments prove that Xiaojin pills can be used in drugs for treating and / or preventing abdominal aortic aneurysm, and an effective novel potential alternative method is provided for prevention and treatment of abdominal aortic aneurysm.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of biomedicine, and in particular to the use of Xiaojin Pills in preparing a medicine for treating and / or preventing abdominal aortic aneurysm. Background Art

[0002] Abdominal aortic aneurysm (AAA) is a fatal cardiovascular disease characterized by permanent dilation of the abdominal aorta, with a mortality rate of about 80% after rupture. If not effectively treated, AAA will continue to grow until the aneurysm ruptures. Age, male sex, family history of AAA, smoking and hypertension are all risk factors associated with AAA.

[0003] However, to date, there is no clinically available drug that can effectively cure this disease. For patients with an aortic diameter greater than 5.5 cm, surgical repair is recommended, and for patients with an aortic diameter of 3.0-5.4 cm, defined as a small AAA, only close monitoring is possible. Despite advances in surgical options and several drugs, such as doxycycline, ACEI, and statins, which have been proposed to prevent AAA, there is no proven drug for pharmacological intervention of AAA.

[0004] Therefore, it is necessary to find medical care to prevent the occurrence of AAA and effectively inhibit the expansion of AAA. Summary of the invention

[0005] The present application provides the use of Xiaojin Pills in preparing a medicine for treating and / or preventing abdominal aortic aneurysm.

[0006] This application uses elastase and angiotensin II to construct two mouse abdominal aortic aneurysm models, and simultaneously administers different concentrations of Xiaojin Pills for drug treatment to detect the growth inhibitory effect of Xiaojin Pills on mouse abdominal aortic aneurysms. The test results show that Xiaojin Pills can inhibit the growth and incidence of abdominal aortic aneurysms. Therefore, Xiaojin Pills can be used in drugs for the treatment and / or prevention of abdominal aortic aneurysms.

[0007] Wherein, the drug is capable of inhibiting the diameter of the abdominal aorta.

[0008] Wherein, the drug can inhibit the incidence of abdominal aorta.

[0009] Among them, the Xiaojin pill has the effect of protecting the function of vascular smooth muscle cells.

[0010] Among them, the small gold pill has the effect of protecting elastic fibers and inhibiting the breakage and degradation of elastic fibers.

[0011] Among them, the Xiaojin pill has the effect of inhibiting tumor formation.

[0012] Optionally, the abdominal aortic aneurysm is an elastase-induced abdominal aortic aneurysm.

[0013] Optionally, the abdominal aortic aneurysm is an abdominal aortic aneurysm caused by angiotensin II.

[0014] In summary, the beneficial technical effects of this application are as follows: The present application confirms through animal experiments that Xiaojin Pills can be used in drugs for treating and / or preventing abdominal aortic aneurysms, providing an effective new potential alternative method for the prevention and treatment of abdominal aortic aneurysms. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 These are the experimental results of each group of elastase model mice (including control-blank treatment group; AAA-model group; NGN-positive drug control group, 50 mg / kg / day; XJW(H)-Xiaojinwan high-dose group, 900 mg / kg / day; XJW(L)-Xiaojinwan low-dose group, 300 mg / kg / day; A is the sample picture at the end point of the experiment; B is the comparative analysis of the abdominal aorta diameter, Mean±SEM, *P<0.05, **P<0.01).

[0016] Figure 2 The results of HE staining and EVG staining of each group of elastase model mice.

[0017] Figure 3 The body weight changes of each group of elastase model mice on the 1st, 5th, 9th and 13th days.

[0018] Figure 4 These are the experimental results of each group of angiotensin II buried pump model mice (including control-blank treatment group; AngⅡ-model group; AngⅡ+NGN-positive drug control group, 50 mg / kg / day; AngⅡ+XJW-Xiaojinwan low-dose group, 300 mg / kg / day; A is the sample picture at the end point of the experiment; B is the comparative analysis of the abdominal aorta diameter, Mean±SEM, *P<0.05, **P<0.01).

[0019] Figure 5 The statistical results of the incidence of abdominal aortic aneurysm among the groups of angiotensin II buried pump model mice (Chi-square, *P<0.05).

[0020] Figure 6 This is the blood pressure status of each group of angiotensin II buried pump model mice.

[0021] Figure 7 These are the results of HE staining and EVG staining in each group of angiotensin II buried pump model mice.

[0022] Figure 8 The figure shows the changes in body weight of each group of angiotensin II buried pump model mice on days 1, 8, 15 and 22. DETAILED DESCRIPTION

[0023] Before describing the embodiments of the present application in detail, it should be understood that the terms used herein are only used for the purpose of describing specific embodiments. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by ordinary technicians in the field to which the terms belong.

[0024] Xiaojin Pills is a prescription of Wang Hongxu, a famous doctor in the Qing Dynasty. It can treat yin carbuncle, such as thyroid nodules, uterine fibroids, ovarian cysts, etc. The main ingredients of Xiaojin Pills are artificial musk, Momordica cochinchinensis (shelled and oiled), processed aconite, maple resin, frankincense (processed), myrrh (processed), tsaoko (fried with vinegar), angelica (fried with wine), earthworms, and fragrant ink. Xiaojin Pills can disperse stagnation and reduce swelling, dissipate blood stasis and relieve pain. It is used for scrofula, goiter, breast rock, breast lumps caused by stagnation of phlegm and qi. Symptoms include one or more lumps on the skin or under the skin, which move when pushed, or swelling of bones and joints, unchanged skin color, swelling and pain.

[0025] Through bioinformatics analysis, this application found that Xiaojin Wan was significantly negatively correlated with the dysregulated expression of abdominal aortic aneurysm genes, so Xiaojin Wan may be able to reverse the dysregulated genes of abdominal aortic aneurysm, further suggesting that Xiaojin Wan may be used in drugs for the treatment and / or prevention of abdominal aortic aneurysm.

[0026] Based on this, this application further conducted a feasibility study.

[0027] This application is the first to study the association between Xiaojin Wan and abdominal aortic aneurysm. Through the study, it is found that Xiaojin Wan can be used in drugs for the treatment and / or prevention of abdominal aortic aneurysm.

[0028] In the present application, the drug Xiaojin Wan used is prior art and can be purchased on the market.

[0029] The present application provides the use of Xiaojin Pills in preparing a medicine for treating and / or preventing abdominal aortic aneurysm.

[0030] Wherein, the drug is capable of inhibiting the diameter of the abdominal aorta.

[0031] Wherein, the drug can inhibit the incidence of abdominal aorta.

[0032] Wherein, the abdominal aortic aneurysm is an abdominal aortic aneurysm caused by elastase.

[0033] Wherein: the abdominal aortic aneurysm is an abdominal aortic aneurysm caused by angiotensin II.

[0034] Among them, the Xiaojin pill has the effect of protecting the function of vascular smooth muscle cells.

[0035] Among them, the small gold pill has the effect of protecting elastic fibers and inhibiting the breakage and degradation of elastic fibers.

[0036] Among them, the Xiaojin pill has the effect of inhibiting tumor formation.

[0037] In order to make the purpose, technical solutions and advantages of this application clearer, the technical solutions in the embodiments of this application are clearly and completely described below in conjunction with the accompanying drawings. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without making creative work are within the scope of protection of this application.

[0038] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0039] The present application is further described in detail below in conjunction with the embodiments, drawings and test results.

[0040] In the following examples, the experimental animals included C57BL / 6J mice, ApoE − / − Mouse.

[0041] C57BL / 6J mice, 20-25 g, SPF grade, male, were purchased from the Experimental Animal Center of Peking University Health Science Center.

[0042] ApoE − / − Mice, 30-35 g, SPF grade, male, were purchased from the Experimental Animal Center of Peking University Health Science Center.

[0043] In the following examples, the manufacturer of Xiaojin Wan is Chengdu Yongkang Pharmaceutical Co., Ltd.; the manufacturer of the positive control drug naringenin is Sigma (USA); the manufacturer of elastase is Sigma (USA); and the manufacturer of angiotensin II is MCE (USA). Example Example 1

[0044] This example explores the inhibitory effect of Xiaojin Wan on the elastase model group.

[0045] The specific process includes the following: (1) Experimental groups The experimental animals were randomly divided into a blank treatment group (control), a model group (AAA), a positive drug control group (NGN, 50 mg / kg / day), a Xiaojinwan high-dose group (XJW(H), 900 mg / kg / day), and a Xiaojinwan low-dose group (XJW(L), 300 mg / kg / day).

[0046] (2) Drugs and administration methods Naringenin: Dissolve an appropriate amount in physiological saline to prepare 16 mg / mL. Prepare before use and store in dark place.

[0047] Xiaojin Pills: Take an appropriate amount of pills, break them into pieces, put them into a glass bottle with a rotor, add an appropriate amount of physiological saline, heat and stir for 30 minutes, and prepare to 0.3g / mL. Prepare before use.

[0048] The dosage is as follows: The drug was administered three days before the establishment of the elastase model mice.

[0049] Model group: Each animal was intragastrically administered with an equal volume of saline every day.

[0050] Positive drug control group: Each animal was intragastrically administered with a dose of 50 mg / kg / day.

[0051] Xiaojin Pill high-dose group: Each animal was intragastrically administered with a dose of 900 mg / kg / day.

[0052] Xiaojin Pill low-dose group: Each animal was intragastrically administered with a dose of 300 mg / kg / day.

[0053] (3) Abdominal aortic aneurysm model - elastase model 1) Prepare high-pressure surgical instruments, cotton pads, gloves, and sterile saline before the experiment; 2) 8-10 week old mice were anesthetized with 1% sodium pentobarbital (about 1.5 ml / mouse) intraperitoneally and fixed to a mouse board with tape; 3) Remove hair from the abdomen with depilatory cream, wait for 3-5 minutes after applying the depilatory cream, and wipe it with toilet paper until all the hair is removed; 4) Open the abdomen, carefully cut open the abdominal skin, gently stir with a cotton swab to create space, find the infrarenal abdominal aorta, gently tear open the connective tissue outside the blood vessel, and separate the infrarenal abdominal aorta; 5) Use tweezers to pass the 0.5cm wide glove strip under the blood vessel, and pass the 0.3-0.5cm wide cotton strip under the blood vessel, and place it between the glove strip and the blood vessel, removing the excess cotton strip stained with blood, and try to prevent the cotton strip wrapped around the blood vessel from being stained with too much blood; 6) Add 30ul of elastase (4.5U) onto the infrarenal abdominal aorta of the mouse that has passed through the glove strip and cotton pad, and wrap it with cotton pad and glove strip for 40 minutes; 7) Remove the cotton pad and gloves, use a syringe to drip a small amount of clean saline to flush the abdominal cavity, drip penicillin-containing saline on the wound to prevent infection, and suture the wound. After 14 days, take samples, anesthetize and draw blood, perfuse and fix, isolate the mouse aorta and place it in paraformaldehyde; take gross photos.

[0054] (4) Observation indicators Abdominal aortic aneurysm is defined as dilation of the abdominal aorta to 1.5 times or more of its normal diameter.

[0055] Elastase model group: During the experiment, attention was paid to the activity, diet and other conditions of each mouse. The body weight of each mouse was measured every 4 days, and the diameter of the abdominal aorta of each mouse was measured after sampling.

[0056] (5) Statistical methods ImageJ software was used to measure the diameter of the abdominal aorta of each blood vessel, and Graphpad was used for data statistical analysis. One-way ANOVA was used, *p<0.05, **p<0.01; Chi-square was used to calculate the differences in incidence among the groups, *p<0.05, **p<0.01. Example 2

[0057] This example investigates the inhibitory effect of Xiaojin Wan on the angiotensin II buried pump model.

[0058] The specific process includes the following: (1) Experimental groups The experimental animals were randomly divided into a blank treatment group (control), a model group (AngⅡ), a positive drug control group (AngⅡ+NGN, 50 mg / kg / day), and a Xiaojinwan low-dose group (AngⅡ+XJW, 300 mg / kg / day).

[0059] (2) Drugs and administration methods Naringenin: Dissolve an appropriate amount in physiological saline to prepare 16 mg / mL. Prepare before use and store in dark place.

[0060] Xiaojin Pills: Take an appropriate amount of pills, break them into pieces, put them into a glass bottle with a rotor, add an appropriate amount of physiological saline, heat and stir for 30 minutes, and prepare to 0.3g / mL. Prepare before use.

[0061] The dosage is as follows: Drug administration began seven days before the establishment of the elastase model mice.

[0062] Model group: Each animal was intragastrically administered with an equal volume of saline every day.

[0063] Positive drug control group: Each animal was intragastrically administered with a dose of 50 mg / kg / day.

[0064] Xiaojin Pill low-dose group: Each animal was intragastrically administered with a dose of 300 mg / kg / day.

[0065] (3) Abdominal aortic aneurysm model - angiotensin II buried pump model AngⅡ pump infusion; the dosage for each mouse is 1000ng / kg / min. Prepare AngⅡ mother solution according to the weight of the mouse with the largest body weight, and dilute the rest with appropriate amount of saline in proportion (dissolve with saline in a clean bench and place the solution on ice). Use a syringe to inject the AngII solution into the pre-soaked sustained-release pump and insert it into the cover of the pump. Soak the pump in saline for 12 hours before surgery and place it in a 37℃ incubator.

[0066] Pump implantation surgery: 1) Before the operation, prepare sterile surgical instruments, needles and threads, sterile saline, 75% alcohol, beakers, dishes, 1% sodium pentobarbital solution, cotton swabs, 1mL syringes, etc.; 2) Mice were anesthetized with 1% sodium pentobarbital; 3) Hair removal on the back of the neck, disinfect the skin with alcohol; 4) Use scissors to open the skin, use a needle holder to dilate the skin, and insert the sustained-release pump with the cap facing inward; 5) Suture the wound, observe the condition of the mice every day after surgery (whether there is death), and gently massage the location where the pump is buried every day to prevent the pump from adhering to the skin; 6) After 28 days, the mice were weighed and blood pressure was measured, blood was collected after anesthesia, and after perfusion fixation, the aorta of the mice was isolated and placed in paraformaldehyde; gross photographs were taken.

[0067] (4) Observation indicators Abdominal aortic aneurysm is defined as dilation of the abdominal aorta to 1.5 times or more of its normal diameter.

[0068] Angiotensin II implanted pump group: During the experiment, the death of each mouse was monitored, and whether each mouse died due to aortic aneurysm rupture was recorded. The blood pressure of each mouse was measured before sampling. The body weight of each mouse was measured every 7 days, and the diameter of the abdominal aorta of each mouse was measured after sampling, and the incidence and other indicators were statistically analyzed.

[0069] (5) Statistical methods ImageJ software was used to measure the diameter of the abdominal aorta of each blood vessel, and Graphpad was used for data statistical analysis. One-way ANOVA was used, *p<0.05, **p<0.01; Chi-square was used to calculate the differences in incidence among the groups, *p<0.05, **p<0.01. Test results

[0070] The test results of Example 1 and Example 2 are shown in Table 1 and Figure 1-8 shown.

[0071] Figure 1The experimental results of each group of elastase model mice are shown in Figure A. Figure A is a photograph of the elastase model mice at the end of the experiment, and Figure B is a comparative analysis of the diameter of the abdominal aorta of the elastase model mice. Figure 1 It can be seen that the diameter of the abdominal aorta in the positive drug control group of naringenin was significantly lower than that in the model group (p<0.01). At the same time, the high-dose (p<0.01) and low-dose (p<0.05) Xiaojinwan groups could also significantly reduce the dilatation of the abdominal aorta in mice caused by elastase.

[0072] Figure 2 The results of HE staining and EVG staining of each group of elastase model mice are shown in Figure 2. Figure 2 It can be seen from the results of HE staining that the control group is a normal aorta, and the smooth muscle cell layer is tightly connected by elastic fibers and collagen fibers, while the artery in the AAA group is irregular in shape and the vascular media is almost gone, which is due to the degradation of matrix proteins in the tube wall and the decrease in elasticity. In the XJW (H) group and the XJW (L) group, the vascular media is well preserved, and the smooth muscle cell layer is not obviously loose or disappearing, which shows that Xiaojin Pills has a good effect in protecting the function of vascular smooth muscle cells. At the same time, from the results of EVG staining, it can be seen that the elastic fibers in the control group are deeply stained and the aortic elastic fiber content is normal, while the elastic fibers in the AAA group are the least stained and the aortic elastic fiber content is significantly reduced, and the degree of elastic fiber reduction in the XJW (H) group and the XJW (L) group is significantly inhibited, which shows that Xiaojin Pills can protect elastic fibers and inhibit their degradation.

[0073] Figure 3 The following are the changes in body weight of each group of elastase model mice on days 1, 5, 9, and 13. Figure 3 It can be seen that there is no significant difference in body weight changes among the five groups of mice.

[0074] Figure 4 The experimental results of each group of angiotensin II implanted pump model mice are shown in Figure A. Figure A is a photograph of the end point of the angiotensin II implanted pump model mouse experiment, and Figure B is a comparative analysis of the diameter of the abdominal aorta of the angiotensin II implanted pump model mice. Figure 4 It can be seen that the diameter of the abdominal aorta in the positive drug control group of naringenin was significantly lower than that in the model group (p<0.01). At the same time, the low-dose group of Xiaojin Pills (p<0.05) could also significantly reduce the dilation of the abdominal aorta in mice caused by angiotensin II.

[0075] Figure 5 The following are the statistical results of the incidence of abdominal aortic aneurysms among the various groups of mice with angiotensin II implanted pump model. Figure 5It can be seen that the incidence rate of the model group was 70%, the incidence rate of naringenin in the positive drug control group was 26%, which can significantly reduce the incidence rate of abdominal aortic aneurysm caused by angiotensin II (p<0.01), and the incidence rate of the low-dose Xiaojin Pill group was 36%, which can also significantly reduce the incidence rate of abdominal aortic aneurysm caused by angiotensin II (p<0.05).

[0076] Figure 6 Figure 2 shows the blood pressure of each group of mice with angiotensin II implanted pump model. Figure 6 It can be seen that there is no significant difference in blood pressure among the four groups of mice.

[0077] Figure 7 The results of HE staining and EVG staining of each group of angiotensin II buried pump model mice. Figure 7 It can be seen from the results of HE staining and EVG staining that the aortic elastic fibers in the control group were closely arranged, while in the model group, the elastic fiber plates were broken or even disappeared, and there was obvious tumor formation. The low-dose Xiaojin Pill group could significantly inhibit the breakage of elastic fibers and the formation of tumors.

[0078] Figure 8 The following are the changes in body weight of each group of angiotensin II pump model mice on days 1, 8, 15, and 22. Figure 8 It can be seen that there is no significant difference in body weight changes among the five groups of mice.

[0079] Table 1 The efficacy of Xiaojinwan against abdominal aortic aneurysm

[0080] As shown in Table 1, compared with the model group, the positive control group naringenin can significantly reduce the diameter and incidence of abdominal aortic aneurysm, p < 0.01, and has no significant effect on the blood pressure and body weight of mice. Figure 1-3 It can be seen that the high-dose group of Xiaojin Pills can significantly inhibit the diameter of abdominal aortic aneurysms in elastase model mice, p < 0.01, and has no significant effect on the weight of mice. Figure 5-8 It can be seen that the low-dose group of Xiaojin Pills can significantly inhibit the diameter and incidence of abdominal aortic aneurysm in angiotensin II buried pump model mice, p<0.05, and has no significant effect on the blood pressure and body weight of mice.

[0081] In conclusion, the Chinese patent medicine Xiaojin Wan has an inhibitory effect on the occurrence of abdominal aortic aneurysm caused by both elastase and angiotensin II.

[0082] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit it. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present application.

Claims

1. Use of Xiaojin Pills in the preparation of a medicament for treating and / or preventing abdominal aortic aneurysm.

2. Use of the Xiaojin Pill according to claim 1 in preparing a medicament for treating and / or preventing abdominal aortic aneurysm, characterized in that: The drug is capable of inhibiting the diameter of the abdominal aorta.

3. Use of the Xiaojin Pill according to claim 1 in preparing a medicament for treating and / or preventing abdominal aortic aneurysm, characterized in that: The drug is capable of suppressing the incidence of abdominal aorta.

4. Use of the Xiaojin Pill according to claim 1 in preparing a medicament for treating and / or preventing abdominal aortic aneurysm, characterized in that: The abdominal aortic aneurysm is an abdominal aortic aneurysm caused by elastase.

5. Use of the Xiaojin Pill according to claim 1 in preparing a medicament for treating and / or preventing abdominal aortic aneurysm, characterized in that: The abdominal aortic aneurysm is an abdominal aortic aneurysm caused by angiotensin II.

6. Use of the Xiaojin Pill according to claim 1 in preparing a medicament for treating and / or preventing abdominal aortic aneurysm, characterized in that: The Xiaojin pill has the effect of protecting the function of vascular smooth muscle cells.

7. Use of the Xiaojin Pill according to claim 1 in preparing a medicament for treating and / or preventing abdominal aortic aneurysm, characterized in that: The small gold pill has the function of protecting elastic fibers and inhibiting the breakage and degradation of elastic fibers.

8. Use of the Xiaojin Pill according to claim 1 in preparing a medicament for treating and / or preventing abdominal aortic aneurysm, characterized in that: The Xiaojin pill has the effect of inhibiting tumor formation.

Citation Information

Patent Citations

  • Application of Xiaojin pills to preparation of drugs for treating breast cancer

    CN105079150A

  • Application of cycloastragenol to preparation of drug for inhibiting abdominal aortic aneurysm

    CN108498521A